Developer docs
API playgroundTry for free, no card

Search company profiles

Nucleix

Full company profile

uuid0000rnq

Namestring
Nucleix
Legal namestring
Nucleix Ltd.
Websiteurl
nucleix.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Nucleix (legal entity Nucleix Ltd.) is a privately held, venture-backed molecular diagnostics company founded in 2008, with global headquarters and R&D in Rehovot, Israel and a US commercial office in San Diego, California. The company develops, manufactures, and markets non-invasive liquid biopsy tests for cancer detection and monitoring, serving healthcare providers including urologists, hospitals, cancer centers, and laboratories. Its commercial flagship is Bladder EpiCheck, a urine-based test for monitoring non-muscle invasive bladder cancer (NMIBC) recurrence and detecting upper tract urothelial carcinoma; Lung EpiCheck, a blood-based early lung cancer detection test, is in development.

The products are built on the proprietary EpiCheck platform, a PCR-based epigenetics technology that analyzes DNA methylation patterns in blood or urine. The company reports the platform can detect a single cancer molecule in a background of 200,000 normal molecules, runs on standard lab equipment, and delivers same-day results with an objective numerical score (0–100). Biomarker panels are constructed using bioinformatics and machine learning algorithms applied to methylation data. Reported clinical performance for Bladder EpiCheck includes 91% sensitivity for high-grade cancers, 99% negative predictive value for high-grade cancer, and 84% specificity. The platform holds FDA 510(k) clearance (2023) and CE marking, with CLIA accreditation and ISO 13485:2016 certification supporting US and Israeli operations.

Nucleix monetizes through diagnostic test sales to healthcare providers, hospitals, and laboratories, combining a direct US sales organization targeting hospitals and urology clinics with distribution partnerships across Europe—principally A. Menarini Diagnostics, which covers 40+ countries. Pricing is quote-based and not publicly disclosed. Go-to-market relies heavily on clinical evidence generation: peer-reviewed publications (European Urology Oncology, Chest Journal), conference presentations (EAU, AUA, ESOU), educational webinars, and collaborations with leading medical centers such as Cleveland Clinic, Radboud UMC, Medical University of Vienna, and the University of Sheffield. The company raised approximately $77 million in total capital in 2021–2022 and is backed by investors including OrbiMed, RA Capital Management, Sands Capital, BlackRock, and Aurum Ventures.

Short descriptiontext

Nucleix develops and markets non-invasive liquid biopsy cancer tests using its DNA methylation-based EpiCheck platform, selling Bladder EpiCheck (FDA-cleared, CE-marked) and developing Lung EpiCheck for urologists, hospitals, cancer centers, and laboratories across the US and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, DNA methylation assays, cancer molecular diagnostics, bladder cancer monitoring, non-invasive cancer detection
Industry4 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Test Sales
TypeOne Time License
Description

Nucleix develops, manufactures, and markets non-invasive cancer tests using its EpiCheck technology. Revenue is generated through the sale of Bladder EpiCheck diagnostic tests to healthcare providers, hospitals, and laboratories. The company has received FDA 510(k) clearance for Bladder EpiCheck in the US and CE marking for European distribution.

nucleix.com
2Distribution Partnerships
TypeOne Time License
Description

Revenue generated through strategic distribution partnerships such as with A. Menarini Diagnostics for commercialization and distribution of Bladder EpiCheck across Europe.

nucleix.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Bladder EpiCheck diagnostic test
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed

nucleix.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Bladder EpiCheck
Description

Urine-based test for detection and monitoring of bladder cancer and upper tract urothelial carcinoma. CE-marked for Europe, FDA 510(k) cleared for US.

nucleix.com
+2 more records
Core offering1 text field

Nucleix develops, manufactures, and markets non-invasive molecular diagnostic tests for cancer detection using its proprietary EpiCheck platform based on PCR-based epigenetics and DNA methylation analysis. The company sells Bladder EpiCheck, a urine-based test FDA 510(k) cleared for bladder cancer recurrence monitoring in the US and CE-marked in Europe, and is developing Lung EpiCheck, a blood-based test for early-stage lung cancer detection in high-risk individuals. Tests are sold to healthcare providers including hospitals, urology clinics, cancer centers, and laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 91% sensitivity for high-grade bladder cancers
+4 more records
Product overview1 text field

Nucleix offers a portfolio of non-invasive cancer detection tests built on the EpiCheck technology platform. The core product, Bladder EpiCheck (FDA 510(k) cleared and CE-marked), is a urine-based test for monitoring bladder cancer recurrence using DNA methylation analysis. Lung EpiCheck, currently in development, is a blood-based test for early lung cancer detection. Both products leverage the EpiCheck platform's ultra-sensitive PCR-based epigenetics technology that can detect extremely rare cancerous molecules with high accuracy and objective results.

Product and service2 records
1Bladder EpiCheck
CategoryCancer Diagnostics / Molecular Diagnostics
Description

A non-invasive urine test that detects recurrence of bladder tumors by analyzing DNA methylation patterns. FDA 510(k) cleared for monitoring NMIBC recurrence in the United States and CE-marked for primary and recurrent bladder cancer and upper tract urothelial cancer in Europe. Demonstrates 91% sensitivity for high-grade cancers and 99% NPV. Sold to urologists, hospitals, cancer centers, and laboratories for bladder cancer surveillance.

2Lung EpiCheck
CategoryCancer Diagnostics / Molecular Diagnostics
Description

A blood-based test in development that detects lung tumor DNA circulating in blood by identifying disease-specific DNA methylation markers. Intended for early-stage lung cancer detection in high-risk individuals as a population-wide screening approach. Targeted at healthcare systems, pulmonology departments, and lung cancer screening programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-01
Description

Strategic partnership for commercialization and distribution of Bladder EpiCheck, a urine-based genomic test for early detection and monitoring of bladder and upper tract urothelial cancers across Europe. A. Menarini Diagnostics is a company bringing advanced solutions to the in vitro diagnostic market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration and validation studies for EpiCheck technology in bladder and lung cancer detection programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading medical center collaboration for clinical validation and real-world implementation of Bladder EpiCheck in NMIBC surveillance.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Clinical collaboration for bladder cancer detection studies.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Academic medical center partnership for clinical validation studies.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Academic medical center partnership for clinical validation studies.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

European medical center collaboration for bladder and upper tract urothelial carcinoma studies.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Academic medical center partnership for clinical studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Grail
TypeBroad incumbent
Description

Grail is a multi-cancer early detection (MCED) company developing the Galleri blood test. Highly comparable to Lung EpiCheck's intended use case, with overlapping methylation-based cfDNA technology, and is led by Nucleix's former CCO Michael Vicari.

TypeBroad incumbent
Description

Hologic is a major diagnostics company with strengths in molecular and women's health diagnostics (e.g., Panther system, Aptima assays). Comparable as a larger IVD player with PCR-based platforms serving clinical laboratories globally.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy company offering Guardant360 (tumor profiling) and Shield (CRC screening). Overlaps with Nucleix in oncology blood-based diagnostics but at a much larger commercial scale and broader cancer coverage.

TypeBroad incumbent
Description

Exact Sciences develops Cologuard (CRC screening) and Oncotype DX (cancer treatment selection). Compares to Nucleix as a non-invasive molecular diagnostics company in cancer screening and detection, though at substantially greater scale.

TypeBroad incumbent
Description

NeoGenomics operates a global oncology testing services network offering molecular, FISH, and IHC tests. Comparable to Nucleix as a cancer-focused diagnostics provider, though with a broader service-based model rather than a kit-based product.

TypeOthers
Description

Bio-Techne provides reagents, antibodies, and assay components used in molecular diagnostics and methylation-based assays. Adjacent to Nucleix as an enabling supplier of diagnostic reagents rather than a direct competitor.

TypeDirect peer
Description

MDxHealth is a direct peer offering molecular diagnostic tests for urological cancers, including SelectMDx (prostate) and ConfirmMDx, using methylation-based biomarker technology similar to Nucleix's EpiCheck platform.

TypeBroad incumbent
Description

Cepheid, a Danaher subsidiary, provides PCR-based molecular diagnostic platforms widely used in clinical labs. Its GeneXpert system is a competitor and complementary technology for running PCR-based oncology and infectious disease tests similar to EpiCheck.

TypeBroad incumbent
Description

Natera is a leading oncology and reproductive health liquid biopsy company with products like Signatera (MRD) and Vantage. Comparable to Nucleix in its use of cell-free DNA analysis for cancer detection, though it operates at significantly larger scale and broader scope.

TypeBroad incumbent
Description

bioMérieux is a global in vitro diagnostics company with strong oncology and infectious disease offerings. Relevant peer because it acquired Astute Medical (co-founded by Nucleix CEO Chris Hibberd), demonstrating M&A interest in differentiated diagnostic assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nucleix

Cancer Molecular Diagnosticsnucleix.com

Nucleix develops and markets non-invasive liquid biopsy cancer tests using its DNA methylation-based EpiCheck platform, selling Bladder EpiCheck (FDA-cleared, CE-marked) and developing Lung EpiCheck for urologists, hospitals, cancer centers, and laboratories across the US and Europe.

What Nucleix does

Nucleix (legal entity Nucleix Ltd.) is a privately held, venture-backed molecular diagnostics company founded in 2008, with global headquarters and R&D in Rehovot, Israel and a US commercial office in San Diego, California. The company develops, manufactures, and markets non-invasive liquid biopsy tests for cancer detection and monitoring, serving healthcare providers including urologists, hospitals, cancer centers, and laboratories. Its commercial flagship is Bladder EpiCheck, a urine-based test for monitoring non-muscle invasive bladder cancer (NMIBC) recurrence and detecting upper tract urothelial carcinoma; Lung EpiCheck, a blood-based early lung cancer detection test, is in development.

The products are built on the proprietary EpiCheck platform, a PCR-based epigenetics technology that analyzes DNA methylation patterns in blood or urine. The company reports the platform can detect a single cancer molecule in a background of 200,000 normal molecules, runs on standard lab equipment, and delivers same-day results with an objective numerical score (0–100). Biomarker panels are constructed using bioinformatics and machine learning algorithms applied to methylation data. Reported clinical performance for Bladder EpiCheck includes 91% sensitivity for high-grade cancers, 99% negative predictive value for high-grade cancer, and 84% specificity. The platform holds FDA 510(k) clearance (2023) and CE marking, with CLIA accreditation and ISO 13485:2016 certification supporting US and Israeli operations.

Nucleix monetizes through diagnostic test sales to healthcare providers, hospitals, and laboratories, combining a direct US sales organization targeting hospitals and urology clinics with distribution partnerships across Europe—principally A. Menarini Diagnostics, which covers 40+ countries. Pricing is quote-based and not publicly disclosed. Go-to-market relies heavily on clinical evidence generation: peer-reviewed publications (European Urology Oncology, Chest Journal), conference presentations (EAU, AUA, ESOU), educational webinars, and collaborations with leading medical centers such as Cleveland Clinic, Radboud UMC, Medical University of Vienna, and the University of Sheffield. The company raised approximately $77 million in total capital in 2021–2022 and is backed by investors including OrbiMed, RA Capital Management, Sands Capital, BlackRock, and Aurum Ventures.

Nucleix firmographics

Firmographics
Name
Nucleix
Legal name
Nucleix Ltd.
Website
https://nucleix.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Nucleix develops and markets non-invasive liquid biopsy cancer tests using its DNA methylation-based EpiCheck platform, selling Bladder EpiCheck (FDA-cleared, CE-marked) and developing Lung EpiCheck for urologists, hospitals, cancer centers, and laboratories across the US and Europe.
Ownership category
akta.pro rank

Nucleix industry classification

Industry
Product category
Cancer Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic

Keywords

  • Liquid biopsy diagnostics
  • DNA methylation assays
  • Cancer molecular diagnostics
  • Bladder cancer monitoring
  • Non-invasive cancer detection

Where Nucleix is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Nucleix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Diagnostic Test Sales: Nucleix develops, manufactures, and markets non-invasive cancer tests using its EpiCheck technology. Revenue is generated through the sale of Bladder EpiCheck diagnostic tests to healthcare providers, hospitals, and laboratories. The company has received FDA 510(k) clearance for Bladder EpiCheck in the US and CE marking for European distribution.
  2. Distribution Partnerships: Revenue generated through strategic distribution partnerships such as with A. Menarini Diagnostics for commercialization and distribution of Bladder EpiCheck across Europe.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goBladder EpiCheck diagnostic test

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Nucleix product offering

Product offering

Core offering

Nucleix develops, manufactures, and markets non-invasive molecular diagnostic tests for cancer detection using its proprietary EpiCheck platform based on PCR-based epigenetics and DNA methylation analysis. The company sells Bladder EpiCheck, a urine-based test FDA 510(k) cleared for bladder cancer recurrence monitoring in the US and CE-marked in Europe, and is developing Lung EpiCheck, a blood-based test for early-stage lung cancer detection in high-risk individuals. Tests are sold to healthcare providers including hospitals, urology clinics, cancer centers, and laboratories.

Product overview

Nucleix offers a portfolio of non-invasive cancer detection tests built on the EpiCheck technology platform. The core product, Bladder EpiCheck (FDA 510(k) cleared and CE-marked), is a urine-based test for monitoring bladder cancer recurrence using DNA methylation analysis. Lung EpiCheck, currently in development, is a blood-based test for early lung cancer detection. Both products leverage the EpiCheck platform's ultra-sensitive PCR-based epigenetics technology that can detect extremely rare cancerous molecules with high accuracy and objective results.

Differentiator

Problem solved

Functional benefit

Brands

  • Bladder EpiCheck: Urine-based test for detection and monitoring of bladder cancer and upper tract urothelial carcinoma. CE-marked for Europe, FDA 510(k) cleared for US.
  • Lung EpiCheck
  • EpiCheck

Products and services

  • Bladder EpiCheck A non-invasive urine test that detects recurrence of bladder tumors by analyzing DNA methylation patterns. FDA 510(k) cleared for monitoring NMIBC recurrence in the United States and CE-marked for primary and recurrent bladder cancer and upper tract urothelial cancer in Europe. Demonstrates 91% sensitivity for high-grade cancers and 99% NPV. Sold to urologists, hospitals, cancer centers, and laboratories for bladder cancer surveillance.
  • Lung EpiCheck A blood-based test in development that detects lung tumor DNA circulating in blood by identifying disease-specific DNA methylation markers. Intended for early-stage lung cancer detection in high-risk individuals as a population-wide screening approach. Targeted at healthcare systems, pulmonology departments, and lung cancer screening programs.

Quantifiable outcome

  • 91% sensitivity for high-grade bladder cancers
  • +4 more outcomes

Companies that use Nucleix

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Nucleix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Nucleix partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and secondary.

  • A. Menarini DiagnosticscoreChannel Partner/ Reseller/ Distributor · 1 September 2024Strategic partnership for commercialization and distribution of Bladder EpiCheck, a urine-based genomic test for early detection and monitoring of bladder and upper tract urothelial cancers across Europe. A. Menarini Diagnostics is a company bringing advanced solutions to the in vitro diagnostic market.
  • Cleveland CliniccoreStrategic or Co-development PartnerClinical collaboration and validation studies for EpiCheck technology in bladder and lung cancer detection programs.
  • Radboud UMCcoreStrategic or Co-development PartnerLeading medical center collaboration for clinical validation and real-world implementation of Bladder EpiCheck in NMIBC surveillance.
  • Duke HospitalsecondaryStrategic or Co-development PartnerClinical collaboration for bladder cancer detection studies.
  • University of WashingtonsecondaryStrategic or Co-development PartnerAcademic medical center partnership for clinical validation studies.
  • Vanderbilt UniversitysecondaryStrategic or Co-development PartnerAcademic medical center partnership for clinical validation studies.
  • Fundacio PuigvertsecondaryStrategic or Co-development PartnerEuropean medical center collaboration for bladder and upper tract urothelial carcinoma studies.
  • AMC (Academic Medical Center)secondaryStrategic or Co-development PartnerAcademic medical center partnership for clinical studies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Nucleix competitors and assessment

Company assessment

Broad incumbents

  • Grail: Grail is a multi-cancer early detection (MCED) company developing the Galleri blood test. Highly comparable to Lung EpiCheck's intended use case, with overlapping methylation-based cfDNA technology, and is led by Nucleix's former CCO Michael Vicari.
  • Hologic: Hologic is a major diagnostics company with strengths in molecular and women's health diagnostics (e.g., Panther system, Aptima assays). Comparable as a larger IVD player with PCR-based platforms serving clinical laboratories globally.
  • Guardant Health: Guardant Health is a leading liquid biopsy company offering Guardant360 (tumor profiling) and Shield (CRC screening). Overlaps with Nucleix in oncology blood-based diagnostics but at a much larger commercial scale and broader cancer coverage.
  • Exact Sciences: Exact Sciences develops Cologuard (CRC screening) and Oncotype DX (cancer treatment selection). Compares to Nucleix as a non-invasive molecular diagnostics company in cancer screening and detection, though at substantially greater scale.
  • NeoGenomics: NeoGenomics operates a global oncology testing services network offering molecular, FISH, and IHC tests. Comparable to Nucleix as a cancer-focused diagnostics provider, though with a broader service-based model rather than a kit-based product.
  • Cepheid (Danaher): Cepheid, a Danaher subsidiary, provides PCR-based molecular diagnostic platforms widely used in clinical labs. Its GeneXpert system is a competitor and complementary technology for running PCR-based oncology and infectious disease tests similar to EpiCheck.
  • Natera: Natera is a leading oncology and reproductive health liquid biopsy company with products like Signatera (MRD) and Vantage. Comparable to Nucleix in its use of cell-free DNA analysis for cancer detection, though it operates at significantly larger scale and broader scope.
  • bioMérieux: bioMérieux is a global in vitro diagnostics company with strong oncology and infectious disease offerings. Relevant peer because it acquired Astute Medical (co-founded by Nucleix CEO Chris Hibberd), demonstrating M&A interest in differentiated diagnostic assets.

Others

  • Bio-Techne: Bio-Techne provides reagents, antibodies, and assay components used in molecular diagnostics and methylation-based assays. Adjacent to Nucleix as an enabling supplier of diagnostic reagents rather than a direct competitor.

Direct peers

  • MDxHealth: MDxHealth is a direct peer offering molecular diagnostic tests for urological cancers, including SelectMDx (prostate) and ConfirmMDx, using methylation-based biomarker technology similar to Nucleix's EpiCheck platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nucleix social profiles

Digital presence

Nucleix compliance and trust

Trust signal

Compliance4 records

Nucleix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nucleix leadership team

Management profile

Number of profiles

Profiles11 records

Nucleix funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nucleix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nucleix

What does Nucleix do?

Nucleix develops, manufactures, and markets non-invasive molecular diagnostic tests for cancer detection using its proprietary EpiCheck platform based on PCR-based epigenetics and DNA methylation analysis. The company sells Bladder EpiCheck, a urine-based test FDA 510(k) cleared for bladder cancer recurrence monitoring in the US and CE-marked in Europe, and is developing Lung EpiCheck, a blood-based test for early-stage lung cancer detection in high-risk individuals. Tests are sold to healthcare providers including hospitals, urology clinics, cancer centers, and laboratories.

Is Nucleix a public or private company?

Nucleix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nucleix founded?

Nucleix was founded in 2008. It employs 11 to 50 people.

Where is Nucleix based?

Nucleix is headquartered in Rehovot, Israel, in the Middle East region.

How does Nucleix make money?

Two revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are distribution Partnerships.

Who are Nucleix's main competitors?

Broad incumbents on record are Grail, Hologic, Guardant Health, Exact Sciences, NeoGenomics, Cepheid (Danaher), Natera and bioMérieux. Bio-Techne is listed as an others. MDxHealth is listed as a direct peer.

Does Nucleix have an API?

No public API is recorded for Nucleix.

What industry is Nucleix in?

Nucleix's product category is Cancer Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech TimesThe Blacklist’s DNA Plot Was Proven Real in 2009: Scientists Beat Fiction by Five YearsAn August 2026 retrospective review by MovieWeb argues that NBC's crime drama The Blacklist accurately depicted real forensic vulnerabilities and law enforcement practices years before the show aired. The analysis highlights how the series' premise regarding DNA fabrication was scientifically validated by Tel Aviv-based company Nucleix in 2009, and its FBI informant structure mirrors the actual Top Echelon Informant Program.openPR.comFuture Perspectives: Key Trends Shaping the Genomic Urine Testing Market up to 2030The genomic urine testing market is projected to grow to $1.8 billion by 2030, with a compound annual growth rate of 12.2%, driven by increasing demand for non-invasive diagnostics and advancements in genomic testing technologies. In September 2024, Italy-based A. Menarini Diagnostics announced a partnership with Israel-based Nucleix Ltd. to commercialize and distribute Bladder EpiCheck, a urine-based genomic test for early detection and monitoring of bladder and upper tract urothelial cancers across Europe. The article also outlines market segmentation, key trends, and leading industry players in this expanding sector.BioSpaceA Study Published in European Urology Oncology Demonstrated Bladder EpiCheck® Can Detect High-Grade Bladder Cancer Recurrences Missed by White Light CystoscopyNucleix announced results of a clinical study published in European Urology Oncology demonstrating that its Bladder EpiCheck liquid biopsy test, when combined with standard white light cystoscopy for non-muscle invasive bladder cancer surveillance, significantly outperformed cystoscopy alone in detecting high-grade recurrences. In 231 high-grade NMIBC patients followed for a median of 16 months across 316 surveillance visits, Bladder EpiCheck detected 92% of high-grade recurrences versus 62% for white light cystoscopy, including 92% of carcinoma in situ cases versus only 38% for standard cystoscopy. The findings suggest the test can identify patients at risk of recurrence who would otherwise receive a false-negative result, enabling earlier intervention and potentially avoiding radical cystectomy.Business Wire BlogA Study Published in European Urology Oncology Demonstrated Bladder EpiCheck® Can Detect High-Grade Bladder Cancer Recurrences Missed by White Light CystoscopyNucleix announced that a clinical study published in European Urology Oncology demonstrated Bladder EpiCheck® significantly outperforms standard white light cystoscopy in detecting high-grade bladder cancer recurrences, detecting 92% versus 62% of cases across 231 patients followed for a median of 16 months. The test was particularly effective at identifying carcinoma in situ (Tis), detecting 92% of cases compared to just 38% missed by standard cystoscopy, potentially enabling earlier intervention and avoiding bladder removal. The company stated it believes Bladder EpiCheck is poised to significantly improve care management for non-muscle invasive bladder cancer patients.PR NewswireA. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in EuropeA. Menarini Diagnostics and Nucleix announced a long-term commercial agreement for exclusive distribution of the Bladder EpiCheck test in Europe. The CE-marked urine test detects primary or recurrent bladder cancer and upper tract urothelial carcinoma, and is included in EAU clinical guidelines. The partnership aims to accelerate adoption and reduce cystoscopy frequency.Business Wire BlogA. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in EuropeA. Menarini Diagnostics and Nucleix announced a long-term commercial agreement for exclusive distribution of the Bladder EpiCheck test in Europe. The CE-marked urine test detects primary and recurrent bladder cancer and is included in EAU clinical guidelines. The partnership aims to accelerate adoption and reduce cystoscopy frequency.San Diego Business JournalNucleix Closes $55M Funding RoundNucleix, a San Diego-based company specializing in cancer detection via liquid biopsy, has secured $55 million in funding from a group of life science investors led by RA Capital Management. The financing will support the advancement of their methylation technology, EpiCheck, particularly in developing Lung EpiCheck for early lung cancer detection. Nucleix aims to improve compliance with updated screening guidelines for high-risk lung cancer patients in the U.S.Business Wire BlogNucleix Announces Recent Advancements in Early Lung Cancer Detection ProgramNucleix announced advancements in its EpiCheck Next Generation Sequencing platform for early lung cancer detection and secured an additional $22 million in funding, bringing its 2021 total capital raised to $77 million. The company also appointed Catherine Schnabel as chief scientific officer to oversee R&D and launched a prospective multi-center clinical study aiming to enroll approximately 5,000 patients.FinSMEsNucleix Secures $55M in FundingNucleix, a liquid biopsy company, raised $55M in funding led by RA Capital Management, with participation from BlackRock, Lilly Asia Ventures, and others. The company will use the funds to advance its methylation technology and develop its lead lung cancer detection product, Lung EpiCheck, with a prospective study planned for 2022 availability.socaltech.comNucleix Nabs $55M For Lung Cancer DetectionNucleix, a San Diego-based startup developing liquid biopsy technology for early lung cancer detection, raised $55M in a funding round. The round was led by RA Capital Management, with participation from BlackRock, Lilly Asia Ventures, and others.